Mylan Debt to Equity Ratio 2006-2018 | MYL

Current and historical debt to equity ratio values for Mylan (MYL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Mylan debt/equity for the three months ending September 30, 2018 was 1.20.
Mylan Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $14.44B $12.07B 1.20
2018-06-30 $14.38B $12.21B 1.18
2018-03-31 $13.58B $13.18B 1.03
2017-12-31 $14.10B $13.31B 1.06
2017-09-30 $13.99B $13.29B 1.05
2017-06-30 $15.39B $12.83B 1.20
2017-03-31 $16.07B $11.66B 1.38
2016-12-31 $16.56B $11.12B 1.49
2016-09-30 $12.97B $11.83B 1.10
2016-06-30 $12.77B $10.33B 1.24
2016-03-31 $7.67B $10.28B 0.75
2015-12-31 $6.30B $9.77B 0.65
2015-09-30 $7.20B $9.82B 0.73
2015-06-30 $7.27B $9.57B 0.76
2015-03-31 $7.13B $9.09B 0.78
2014-12-31 $7.04B $3.28B 2.15
2014-09-30 $7.00B $3.41B 2.05
2014-06-30 $9.22B $3.35B 2.75
2014-03-31 $9.05B $3.19B 2.83
2013-12-31 $8.86B $2.96B 2.99
2013-09-30 $6.81B $3.23B 2.11
2013-06-30 $6.66B $2.95B 2.26
2013-03-31 $6.45B $2.89B 2.23
2012-12-31 $6.11B $3.36B 1.82
2012-09-30 $5.21B $3.62B 1.44
2012-06-30 $5.55B $3.20B 1.74
2012-03-31 $5.29B $3.78B 1.40
2011-12-31 $5.22B $3.51B 1.49
2011-09-30 $4.82B $3.49B 1.38
2011-06-30 $5.18B $3.88B 1.34
2011-03-31 $5.12B $3.92B 1.31
2010-12-31 $5.63B $3.62B 1.56
2010-09-30 $5.67B $3.54B 1.60
2010-06-30 $5.51B $2.98B 1.85
2010-03-31 $5.54B $3.18B 1.74
2009-12-31 $5.47B $3.14B 1.74
2009-09-30 $5.53B $3.07B 1.80
2009-06-30 $5.39B $2.91B 1.85
2009-03-31 $5.37B $2.65B 2.03
2008-12-31 $5.50B $2.79B 1.98
2008-09-30 $5.46B $2.98B 1.83
2008-06-30 $4.95B $3.13B 1.58
2008-03-31 $4.97B $3.16B 1.58
2007-12-31 $4.91B $3.40B 1.44
2007-09-30 $1.61B $1.89B 0.85
2007-06-30 $1.70B $1.73B 0.98
2007-03-31 $1.69B $1.65B 1.02
2006-12-31 $0.71B $1.10B 0.64
2006-09-30 $0.71B $0.96B 0.74
2006-06-30 $0.71B $0.87B 0.82
2006-03-31 $0.71B $0.79B 0.90
2005-12-31 $0.79B $0.76B 1.04
2005-09-30 $0.79B $0.83B 0.95
2005-06-30 $0.02B $1.88B 0.01
2005-03-31 $0.02B $1.85B 0.01
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $16.418B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $46.906B 8.33
Teva Pharmaceutical Industries (TEVA) Israel $18.283B 6.31
Bausch Health Cos (BHC) Canada $8.901B 6.44
Dr Reddy's Laboratories (RDY) India $5.974B 23.83
Supernus Pharmaceuticals (SUPN) United States $2.043B 19.36
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.817B 3.03
Amphastar Pharmaceuticals (AMPH) United States $1.124B 121.90
Homology Medicines (FIXX) United States $0.916B 0.00
CymaBay Therapeutics (CBAY) United States $0.591B 0.00
Assembly Biosciences (ASMB) United States $0.583B 0.00
Akorn (AKRX) United States $0.557B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.414B 0.00
Voyager Therapeutics (VYGR) United States $0.349B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.288B 0.00
Sol-Gel Technologies (SLGL) Israel $0.127B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.092B 0.00
Teligent (TLGT) United States $0.087B 0.00
Acasti Pharma (ACST) Canada $0.071B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.063B 0.00
Evoke Pharma (EVOK) United States $0.053B 0.00
Agile Therapeutics (AGRX) United States $0.037B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.017B 0.00
Aevi Genomic Medicine (GNMX) United States $0.015B 0.00
China Pharma Holdings (CPHI) China $0.012B 0.00